Stage I nonsmall cell lung carcinoma - Analysis of survival and implications for screening

被引:0
|
作者
Dominioni, L
Imperatori, A
Rovera, F
Ochetti, A
Torrigiotti, G
Paolucci, M
机构
[1] Azienda Osped Circolo Varese, Varese, Italy
[2] Univ Insubria, Ctr Thorac Surg, Varese, Italy
关键词
lung carcinoma; Stage I; early diagnosis; overdiagnosis; screening; survival; cure;
D O I
10.1002/1097-0142(20001201)89:11+<2334::AID-CNCR4>3.0.CO;2-I
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND, Skepticism about the radical curability of lung carcinoma, even when diagnosed in Stage I, has been long fostered by the epidemiologists' dogma against lung cancer screening, and by official recommendations not to screen for lung carcinoma. Follow-up of patients with asymptomatic screen-detected Stage I nonsmall cell lung carcinoma (NSCLC), however, shows that patients who underwent radical resection have long term survival rates, whereas patients nonsurgically treated or undergoing suboptimal operations have much poorer prognosis. The latter clinical outcome data strongly suggest the importance of detecting lung carcinoma when it is in Stage I and cast serious doubts on the recommendation not to screen for lung carcinoma. DATA. The scrutiny of the biology, epidemiology, and clinical features of Stage I NSCLC clarifies important aspects of the ongoing controversy concerning the value of screening for early diagnosis (Stage I) of lung carcinoma. The biologic characteristics of Stage I NSCLC (histologic types, doubling time, metastases) indicate its malignant potential. The asymptomatic screen-diagnosed Stage I carcinomas have longer doubling time than the more advanced cancers; nevertheless, they are not overdiagnosed tumors because they cause fatal outcome if they are not resected. Chest X-ray screening identifies approximately 50% of cancers in Stage I. Screening by helical low dose computed tomography scan detects greater than 80% of lung carcinomas in Stage I. The resectability, the surgical techniques (lobectomy vs. limited resections), and the influence of the extent of surgical resection of Stage I NSCLC on prognosis are reviewed. These data show that radical surgical treatment offers 5-year survival rate to 60-80% of patients with Stage I NSCLC. SYNTHESIS. Asymptomatic Stage I lung carcinomas, detected by screening or by incidental findings, are truly malignant, because they metastasize and cause fatal outcome if they are not radically resected. The possibility to cure lung carcinomas relies on radical resection (lobectomy or, less frequently, pneumonectomy) of early diagnosed (Stage I) disease, which is usually asymptomatic. The limited parenchymal resections (segment or wedge resections) do not fulfill the requirements of radicality because they are accompanied by higher incidence of local recurrences and shorter survival rates. CONCLUSIONS. The documented improvement of long term survival of NSCLC, which can be achieved by early diagnosis and radical resection, strongly indicates that the current dogma against lung cancer screening is untrue. Every effort should be made to detect the disease when it is in Stage I and radically operable, by implementing screening in at risk smokers and former smokers, with the most effective screening method that is locally available. Cancer 2000;89:2334-44. (C) 2000 American Cancer Society.
引用
收藏
页码:2334 / 2344
页数:11
相关论文
共 50 条
  • [41] Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening
    Yemelyanova, A. V.
    Cosin, J. A.
    Bidus, M. A.
    Boice, C. R.
    Seidman, J. D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (03) : 465 - 469
  • [42] PROGNOSTIC FACTORS IN SURGICALLY RESECTED LIMITED-STAGE, NONSMALL CELL-CARCINOMA OF THE LUNG
    LIPFORD, EH
    SEARS, DL
    EGGLESTON, JC
    MOORE, GW
    LILLEMOE, KD
    BAKER, RR
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1984, 8 (05) : 357 - 365
  • [43] Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma
    Huang, CI
    Neuberg, D
    Johnson, BE
    Wei, JY
    Christiani, DC
    CANCER, 2003, 98 (01) : 135 - 143
  • [44] STAGE-I NONSMALL CELL LUNG-CANCER - A MULTIVARIATE-ANALYSIS OF TREATMENT METHODS AND PATTERNS OF RECURRENCE
    HARPOLE, DH
    HERNDON, JE
    YOUNG, WG
    WOLFE, WG
    SABISTON, DC
    CANCER, 1995, 76 (05) : 787 - 796
  • [45] Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma
    Shinohara, ET
    Gonzalez, A
    Massion, PP
    Chen, HD
    Li, M
    Freyer, AS
    Olson, SJ
    Andersen, JJ
    Shyr, Y
    Carbone, DP
    Johnson, DH
    Hallahan, DE
    Lu, B
    CANCER, 2005, 103 (08) : 1685 - 1692
  • [46] Bronchioloalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease
    Breathnach, OS
    Kwiatkowski, DJ
    Finkelstein, DM
    Godleski, J
    Sugarbaker, DJ
    Johnson, BE
    Mentzer, S
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (01): : 42 - 47
  • [47] Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients
    Palomares, MR
    Sayre, JW
    Shekar, KC
    Lillington, LM
    Chlebowski, RT
    CANCER, 1996, 78 (10) : 2119 - 2126
  • [48] RADIATION-THERAPY ALONE FOR STAGE-I NONSMALL CELL LUNG-CANCER
    KASKOWITZ, L
    GRAHAM, MV
    EMAMI, B
    HALVERSON, KJ
    RUSH, C
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03): : 517 - 523
  • [49] EXPRESSION OF BLOOD-GROUP ANTIGEN A BY STAGE-I NONSMALL CELL LUNG CARCINOMAS
    RICE, TW
    TUBBS, RR
    HOELTGE, GA
    KIRBY, TJ
    MEEKER, DP
    MEDENDORP, SV
    BUKOWSKI, RM
    ANNALS OF THORACIC SURGERY, 1995, 59 (03): : 568 - 572
  • [50] The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections
    Vallieres, Eric
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (05)